

## Selected Innovative Medicines in Development as of April 16, 2024



## Oncology (1 of 2)

### **RYBREVANT / lazertinib**

Non Small Cell Lung Cancer 2L (MARIPOSA-2)

### **DARZALEX (daratumumab)**

Frontline multiple myeloma transplant eligible (PERSEUS)

### **RYBREVANT (amivantamab)**

Frontline Non Small Cell Lung Cancer in combination with chemotherapy (PAPILLON)

### **TECVAYLI (teclistamab)**

Multiple Myeloma 1-3PLs (MajesTEC-3)

### **AKEEGA (niraparib/abiraterone)**

M1 Metastatic Castration-Sensitive Prostate Cancer (AMPLITUDE)

### **TAR-200 (RIS/gemcitabine plus cetrelimab)**

Muscle Invasive Bladder Cancer (SunRISe-2)

### **ERLEADA (apalutamide)**

High Risk Prostate Cancer (PROTEUS)

### **CARVYKTI (Ciltacabtagene autoleucel)**

Frontline Multiple Myeloma TNI (CARTITUDE-5)

### **RYBREVANT / lazertinib**

Non Small Cell Lung Cancer (MARIPOSA)

### **BALVERSA (erdafitinib)**

Urothelial Cancer (THOR)

### **TECVAYLI (teclistamab)**

Relapsed Refractory Multiple Myeloma CD38 exposed (MajesTEC-9)

### **TALVEY (talquetamab)**

Relapsed Refractory Multiple Myeloma CD38 exposed (MonumentAL-6)

### **IMBRUVICA (ibrutinib)**

Relapsed Refractory patients with Mantle Cell Lymphoma in combination with venetoclax (SYMPATICO)

### **DARZALEX (daratumumab)**

Frontline multiple myeloma transplant ineligible (CEPHEUS)

### **ERLEADA (apalutamide)**

Localized Prostate Cancer (ATLAS)

### **RYBREVANT (amivantamab)**

Subcutaneous (PALOMA-3)

### **IMBRUVICA (ibrutinib)**

Frontline Chronic Lymphocytic Leukemia (I + V fixed duration) (GLOW)

### **CARVYKTI (Ciltacabtagene autoleucel)**

Relapsed Refractory Multiple Myeloma w/1-3 PL (CARTITUDE-4)

### **TECVAYLI (teclistamab)**

TE NDMM maintenance (MajesTEC-4)

### **TALVEY (talquetamab)**

Relapsed Refractory Multiple Myeloma A-CD38 Naïve (MonumentAL-3)

### **TAR-200 (RIS/gemcitabine plus cetrelimab)**

Non Muscle Invasive Bladder Cancer BCG-naïve High Risk (SunRISe-3)

### **DARZALEX (daratumumab)**

Smoldering Multiple Myeloma (AQUILA)

### **CARVYKTI (Ciltacabtagene autoleucel)**

Frontline Multiple Myeloma Transplant Eligible vs ASCT (CARTITUDE-6)

### **TAR-200 (RIS/gemcitabine plus cetrelimab)**

Non Muscle Invasive Bladder Cancer (SunRISe-1)

## Oncology (2 of 2)

---

**JNJ-0683 (ARX788)**

Breast Cancer

**JNJ-0631 (ARX305)**

Renal Cancer

**JNJ-9530**

Hematological Malignancies

**JNJ-1493**

Hematological Malignancies

**JNJ-5322**

Multiple Myeloma

**JNJ-6617**

Hematological Malignancies

**erdafitinib**

Intravesical Delivery System for Localized Bladder Cancer

**JNJ-8177 (ARX517)**

Prostate Cancer

**JNJ-9968**

Hematological Malignancies

**JNJ-9401**

Prostate Cancer

**JNJ-2421**

Solid Tumor Targeted Therapy

**JNJ-6420**

Prostate Cancer

**VAC85135**

Hematological Malignancies

**JNJ-4496**

Hematological Malignancies

**JNJ-0387**

Solid Tumors

**JNJ-8543**

Hematological Malignancies

**JNJ-8343**

Prostate Cancer

**JNJ-4681**

Hematological Malignancies

## Immunology (1 of 2)

---

**TREMFYA (guselkumab)**  
Ulcerative Colitis Monotherapy (QUASAR)

**TREMFYA (guselkumab)**  
Pediatric Juvenile Psoriatic Arthritis

**TREMFYA (guselkumab)**  
Psoriatic Arthritis Structural Damage

**STELARA (ustekinumab)**  
Pediatric Ulcerative Colitis

**nipocalimab**  
Warm Autoimmune Hemolytic Anemia

**nipocalimab**  
Hemolytic Disease of the Fetus and Newborn

**nipocalimab Combination Therapy**  
Rheumatoid Arthritis

**JNJ-4804 Combination Therapy**  
Ulcerative Colitis

**STELARA (ustekinumab)**  
Pediatric Juvenile Psoriatic Arthritis

**TREMFYA (guselkumab)**  
Ulcerative Colitis Subcutaneous Induction (ASTRO)

**TREMFYA (guselkumab)**  
Pediatric Psoriasis

**STELARA (ustekinumab)**  
Pediatric Crohn's Disease

**JNJ-2113**  
Psoriasis

**nipocalimab**  
Sjogren's Disease

**JNJ-4804 Combination Therapy**  
Crohn's Disease

**JNJ-2113**  
Ulcerative Colitis

**TREMFYA (guselkumab)**  
Pediatric Ulcerative Colitis

**TREMFYA (guselkumab)**  
Crohn's Disease Subcutaneous Induction (GRAVITI)

**TREMFYA (guselkumab)**  
Crohn's Disease (GALAXI)

**SIMPONI (golimumab)**  
Pediatric Ulcerative Colitis

**nipocalimab**  
Idiopathic Inflammatory Myopathy

**nipocalimab**  
Systemic Lupus Erythematosus

**JNJ-4804 Combination Therapy**  
Psoriatic Arthritis

**JNJ-4703**  
Atopic Dermatitis

## Immunology (2 of 2)

---

**JNJ-1459**

Psoriasis

**JNJ-4703**

Rheumatoid Arthritis

## Neuroscience

---

### **seltorexant**

Adjunctive treatment for major depressive disorder with insomnia symptoms

### **aticaprant**

Adjunctive Major Depressive Disorder

### **nipocalimab**

Generalized Myasthenia Gravis Pediatrics

### **JNJ-1813**

Epilepsy

### **JNJ-2056 \***

Alzheimer's Disease

### **nipocalimab**

Chronic Inflammatory Demyelinating Polyneuropathy

### **seltorexant**

Probable Alzheimer's with clinically significant agitation/aggression

### **SPRAVATO (esketamine)**

Major Depressive Disorder with Suicidal Ideation Pediatrics

### **JNJ-0376**

Parkinson's Disease

### **nipocalimab**

Generalized Myasthenia Gravis

### **posdinemab**

Alzheimer's Disease

### **P2X7 antagonist**

Bipolar Depression

### **M1 Antagonist**

Psychiatric Disorder

## Select Other Areas

### CABENUVA

HIV Adolescents

### OPSYNVI (macitentan/tadalafil STCT)

Pulmonary Arterial Hypertension (A DUE)

### macitentan

Pulmonary Arterial Hypertension 75mg (UNISUS)

### milvexian (Factor Xla)

Acute Coronary Syndrome

### JNJ-1802

Dengue Prophylaxis

### OPSUMIT (macitentan)

Pediatric Pulmonary Arterial Hypertension  
(TOMORROW)

### UPTRAVI (selexipag)

Pediatric Pulmonary Arterial Hypertension (SALTO)

### VAC52416

Multivalent ExPEC Vaccine

### milvexian (Factor Xla)

Secondary Stroke Prevention

### prostacyclin receptor agonist

Pulmonary Arterial Hypertension

### EDURANT (rilpivirine)

HIV pediatric 2-12 year old

### RPGR Gene Therapy

Retinitis Pigmentosa

### milvexian (Factor Xla)

Atrial Fibrillation

### JNJ-1887 sCD59

Geographic Atrophy

\*This information is as of April 16, 2024 to the best of the Company's knowledge. Johnson & Johnson assumes no obligation to update this information. \*AC Immune ACI-35.030. Strategic Partnerships, Collaborations, and Licensing arrangements - XARELTO: Bayer; milvexian: Bristol Myers Squibb; X-Linked Retinitis Pigmentosa (AAV-RPGR): MeiraGTx; JNJ-1887: Hemera Biosciences; COMPLERA / EVIPLERA, ODEFSEY, SYMTUZA, PREZCOBIX / REZOLSTA FDC: Gilead Sciences; JULUCA and Long acting HIV injectable treatment regimen of rilpivirine and cabotegravir: ViiV Healthcare; Cloudbreak antiviral conjugates (AVCs); ExPEC: Sanofi; REMICADE and SIMPONI/SIMPONI ARIA: Schering-Plough (Ireland) Company, a subsidiary of Merck & Co., Inc. and Mitsubishi Tanabe Pharma Corporation; TREMFYA: MorphoSys AG; JNJ-2113: Protagonist Therapeutics; Tau Vaccine: AC Immune SA; JNJ-1813: Addex Pharmaceuticals; IMBRUVICA: Pharmacyclics, LLC, an AbbVie company; ZYTIGA: BTG International; VELCADE: Millennium, The Takeda Oncology Company; DARZALEX and DARZALEX FASPRO; Genmab A/S; BALVERSA: Astex Pharmaceuticals; ERLEADA: Regents of California and Memorial Sloan Kettering; CARVYKTI: Legend Biotech; AKEEGA: TESARO, an oncology-focused business within GSK; lazertinib: Yuhan Corporation; Duobody Platform bispecific antibody programs: Genmab A/S; ENHANZE platform; Halozyme Therapeutics; XmAb CD28 bispecific antibodies; Xencor; iPSC-derived chimeric antigen receptor (CAR) NK and CAR T-cell product candidates: Fate Therapeutics; UPTRAVI and OPSUMIT: Nippon Shinyaku (co-promotion in Japan); JNJ-1459: X-CHEM; JNJ-1802: KU Leuven Rega Institute, the KU Leuven Centre for Drug Design and Discovery (CD3), Department of Virology at the Biomedical Primate Research Centre, Department of Infectious Diseases at Heidelberg University, Sealy Institute for Vaccine Sciences at the University of Texas Medical Branch Health (UTMB), Unité des Virus Émergents at Aix-Marseille University and the Walter Reed Army Institute of Research.